SCHEMBL2040436

SCHEMBL2040436

COc1ncc(NCc2ccccc2O)cc1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.58
KDM4E B2RXH2 5/20 0.56
HPGD P15428 4/20 0.56
ALDH1A1 P00352 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
HTT P42858 3/20 0.56
NPC1 O15118 2/20 0.56
LMNA P02545 2/20 0.56
RAB9A P51151 2/20 0.56
GFER P55789 1/20 0.56
L3MBTL1 Q9Y468 2/20 0.49
GAA P10253 2/20 0.49
TDP1 Q9NUW8 1/20 0.49
GPR55 Q9Y2T6 1/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
EGFR P00533 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2038838 0.86 KDM4E (0.55) MAPTKDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL2037443 0.83 MAPT (0.64) MAPTKDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL2037438 0.81 MAPT (0.61) MAPTKDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL2039170 0.81 MAPT (0.61) MAPTKDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL2038654 0.79 MAPT (0.58) MAPTKDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL2040082 0.78 KDM4E (0.56) MAPTKDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL2040847 0.78 MAPT (0.57) MAPTKDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL2041310 0.76 HPGD (0.59) MAPTKDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL27912688 0.73 MAPT (0.66) MAPTKDM4EHPGDSMN1; SMN2HTT
SCHEMBL2044844 0.73 MAPT (0.66) MAPTKDM4EHPGDALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9120753-B2 Phenol derivatives and pharmaceutical or cosmetic use thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2015-09-01 US claimed
US-20130172564-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-07-04 US claimed
EP-2516399-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF Galderma Research & Development (FR) 2012-10-31 EP claimed
WO-2011077044-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-06-30 WO claimed
EP-2516399-B1 PHENOLIC DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RES & DEV (FR) 2018-04-18 EP disclosed
US-9120753-B2 Phenol derivatives and pharmaceutical or cosmetic use thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2015-09-01 US disclosed
US-20130172564-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-07-04 US disclosed
EP-2516399-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF Galderma Research & Development (FR) 2012-10-31 EP disclosed
WO-2011077044-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172564-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF TYR, MITF, CUTA MAPT 775/4885KDM4E 1468/4885HPGD 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.